Women’s Health Dx
Sera Prognostics Completes $100 Million Series E Financing
April 28, 2021-Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test. Read More >
Sera Prognostics Appoints Benjamin G. Jackson as General Counsel
April 13, 2021-Highly accomplished attorney joins Sera to develop its legal and intellectual property functions. Read More >
SERA PROGNOSTICS APPOINTS ROBERT G. HARRISON AS CHIEF INFORMATION OFFICER
March 31, 2021- Accomplished technology leader joins Sera to build and deploy its information strategy. Read More >
WHO WE ARE
PROVIDING INDIVIDUALIZED RISK ASSESSMENT TO PREDICT AND MANAGE PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS
Sera Prognostics is dedicated to improve the lives of women and babies through individualized prenatal care. Sera’s strategy is to deliver pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Our first test, the PreTRM® Test, focuses on the early prediction of preterm birth risk, one of the most serious pregnancy complications which affects almost one in ten pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better understand risks and proactively address risks of adverse pregnancy outcomes. Learn about the PreTRM® Test for Risk Management.